Varian Medical Systems to exhibit its full range of detectors at RSNA Annual Meeting in Chicago

NewsGuard 100/100 Score

Varian Medical Systems, Inc. (NYSE: VAR), a premier supplier of X-ray tubes and flat panel digital image detectors, will exhibit its full range of detectors at the RSNA Annual Meeting in Chicago, Ill. from November 29 - December 3, 2009. Varian will also be exhibiting X-ray tube technology for multiple modalities as well as specialized cancer treatment technologies.

Varian's exhibit will showcase the latest X-ray technology including:

  • A broad array of X-ray tubes with applications for CT scanners, radiographic/fluoroscopic imaging, special procedures and mammography.
  • PaxScan dynamic X-ray detectors designed for use in cardiology, angiography, cone-beam CT, surgical C-arms, and image-guided radiation therapy (IGRT).
  • PaxScan radiographic X-ray detectors intended for use in capturing large fields of view, with applications in radiographic tables, wall stands, and mobile imaging systems.

"We've expanded our PaxScan portfolio and added a 43cm x 36cm hand-held portable radiographic panel with enhanced features," said Steve Kimmel, Vice President X-Ray Products Marketing. "The new panel reflects our continued commitment to build comprehensive digital imaging products in response to the medical community's requirements for improved workflow and productivity."

Varian will also exhibit new technology enhancements designed to make radiotherapy and radiosurgery treatments faster, more accurate, and easier to plan and deliver. The company's solutions for radiotherapy treatment planning, image guidance, treatment delivery, and information and patient record management will all be on display. This exhibit will include RapidArc® technology, which is now in use at over 270 cancer treatment centers worldwide for delivering radiotherapy and radiosurgery, to treat lung, liver, kidney, spine, and brain cancer more quickly and precisely than was possible with earlier technologies.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer